SCHEMBL31185337

SCHEMBL31185337

O=C1Nc2nc(Cl)ccc2C2(CCN(C(=O)OCc3ccccc3)CC2)O1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
OPRK1 P41145 2/20 0.43
OPRD1 P41143 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
ENPP2 Q13822 2/20 0.42
ATXN2 Q99700 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
F11 P03951 6/20 0.41
CYP2C19 P33261 1/20 0.40
GRIN2B Q13224 1/20 0.40
HDAC1 Q13547 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HDAC8 Q9BY41 1/20 0.40
XIAP P98170 1/20 0.39
BIRC2 Q13490 1/20 0.39
ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1813226 1.00 KCNH2 (0.46) KCNH2MEN1KMT2ANPSR1OPRK1
SCHEMBL12655358 0.89 KCNH2 (0.50) KCNH2MEN1KMT2ANPSR1OPRK1
SCHEMBL2525906 0.81 KCNH2 (0.48) KCNH2MEN1KMT2ANPSR1OPRK1
SCHEMBL4134071 0.80 MEN1 (0.55) MEN1KMT2ANPSR1OPRK1OPRD1
SCHEMBL2526690 0.79 MEN1 (0.41) KCNH2MEN1KMT2ANPSR1OPRK1
SCHEMBL8313978 0.75 SIGMAR1 (0.60) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL350330 0.74 OPRK1 (0.47) KCNH2MEN1KMT2ANPSR1OPRK1
SCHEMBL9984601 0.72 P2RX4 (0.37) KCNH2MEN1KMT2ANPSR1OPRK1
SCHEMBL16931095 0.72 MEN1 (0.53) MEN1KMT2ANPSR1OPRK1OPRD1
SCHEMBL11368285 0.71 LMNA (0.57) MEN1KMT2ANPSR1OPRK1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4714499-A2 POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF Jiangsu NHWA Pharmaceutical Co., Ltd (CN) 2026-03-25 EP disclosed
US-20250230129-A1 POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF JIANGSU NHWA PHARMACEUTICAL CO., LTD (CN) 2025-07-17 US disclosed
EP-4497754-A1 POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF Jiangsu NHWA Pharmaceutical Co., Ltd (CN) 2025-01-29 EP disclosed
CN-118891270-A Polyamide compound, preparation method and medical application thereof 江苏恩华药业股份有限公司 2024-11-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230129-A1 POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF ADCYAP1R1, PAICS, AGPS KCNH2 1450/4885MEN1 67/4885KMT2A 1368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.